<DOC>
	<DOCNO>NCT00000712</DOCNO>
	<brief_summary>Original design : The study 's purpose compare effect zidovudine ( AZT ) alone combination AZT acyclovir ( ACV ) determine AZT/ACV associate low death rate few AIDS relate opportunistic infection compare AZT alone , investigate effect treatment plan cytomegalovirus ( CMV ) Epstein-Barr virus ( EBV ) infection . The study evaluate two dos AZT use alone versus two dos AZT combine ACV . Per 12/11/92 amendment : Another antiretroviral agent may substitute AZT . AZT show increase life span patient AIDS advance AIDS relate complex patient treat Pneumocystis carinii pneumonia . Drugs increase effectiveness AZT HIV may also decrease need high dos AZT . This might reduce negative effect AZT reduce positive effect .</brief_summary>
	<brief_title>A Multicenter , Double Blind , Comparative Study Zidovudine Alone Versus Zidovudine Acyclovir Treatment HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3</brief_title>
	<detailed_description>AZT show increase life span patient AIDS advance AIDS relate complex patient treat Pneumocystis carinii pneumonia . Drugs increase effectiveness AZT HIV may also decrease need high dos AZT . This might reduce negative effect AZT reduce positive effect . AMENDED : Patients randomly assign one two treatment regimen . They receive AZT ( antiretroviral agent ) without ACV . Treatment Plan 1 : AZT along placebo time . Treatment Plan 2 : AZT ACV . Therapy 104 week optional extension 24 week end study whichever come first . The maximum duration therapy patient 128 week . Medication dispense biweekly basis first 4 week , every month remainder study . Original design : Patients randomly assign one four treatment plan receive AZT alone AZT ACV . Medications give every 4 hour ( q4h ) orally ( PO ) awake ( WA ) . A total 5 doses/day give . The per dose schedule four plan : Treatment plan 1 : AZT plus placebo ( inactive medication ) substitute ACV . Treatment plan 2 : AZT AZT placebo along ACV placebo . Treatment plan 3 : AZT ACV . Treatment plan 4 : AZT AZT placebo ACV .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Methadone maintenance . Therapies available expanded access treatment IND program unless specifically exclude . Allowed within 30 day study entry : Systemic steroid give treatment Pneumocystis carinii pneumonia . Recommended : PCP prophylaxis . Patient must : Recovered first episode histologically proven Pneumocystis carinii pneumonia ( PCP ) microbiologically proven AIDSdefining opportunistic infection define Centers Disease Control HIV classification group IV . C1 . Study entry must within 120 day AIDSdefining diagnosis . Written documentation positive antibody HIV federally license ELISA test kit . This test confirm another method , example , Western blot , radioimmunoassay ( RIA ) , HIV culture . Patients transfusion dependent ( require blood transfusion per month ) . The last transfusion must &gt; 2 week entry . AMENDED 900827 include HIV positive patient CD4+ count &lt; 200 cells/mm3 . Prior Medication : Allowed : Zidovudine ( AZT ) &lt; 365 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow exclude : Symptomatic visceral progressive Kaposi 's sarcoma ( KS ) ( define &gt; 10 new lesion 30 day prior entry ) . Other concurrent neoplasm basal cell carcinoma skin ( patient complete remission 1 year malignancy may enrol ) . Malabsorption define persistent diarrhea &gt; 6 stools/day &gt; 4 week . Patients whose sole AIDSdefining condition constitutional disease define CDC 's HIV group IVA neurologic disease define CDC 's HIV group IVB AIDSassociated malignancy define CDC 's HIV group IVC . Concurrent Medication : Excluded : Acyclovir ( ACV ) prophylaxis frequent ( &gt; per month ) repeat course ACV therapy herpes simplex virus infection . Any concomitant medicine unless require . Systemic therapy/prophylaxis/maintenance AIDSdefining opportunistic infection prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Acetaminophen &gt; 72 hour . Cimetidine . Flurazepam . Indomethacin . Ranitidine . Probenecid ( receive AZT ) . Rifampin . Rifampinrelated drug . Patients follow exclude : Active opportunistic infection . Symptomatic visceral progressive Kaposi 's sarcoma ( KS ) ( define &gt; 10 new lesion 30 day prior entry ) . Other concurrent neoplasm basal cell carcinoma skin ( patient complete remission 1 year malignancy may enrol ) . Malabsorption define persistent diarrhea &gt; 6 stools/day &gt; 4 week . Patients whose sole AIDSdefining condition constitutional disease define CDC 's HIV group IVA neurologic disease define CDC 's HIV group IVB AIDSassociated malignancy define CDC 's HIV group IVC . Prior Medication : Excluded : Zidovudine ( AZT ) &gt; 365 day prior study entry . Excluded within 14 day study entry : Systemic acyclovir ( ACV ) therapy . Excluded within 30 day study entry : Antiretroviral therapy ( AZT per ) . Immunomodulating agent . Biologic response modifier . Excluded within 60 day study entry : Ribavirin . Prior Treatment : Excluded within 30 day study entry : Cytotoxic chemotherapy radiation therapy Kaposi 's sarcoma . Active substance abuse would impair compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Herpesvirus 4 , Human</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>